On the 21st, Lin BioScience announced on behalf of its subsidiary Belite Bio that the U.S. FDA has granted Breakthrough Therapy Designation to LBS-008 (Tinlarebant), its investigational drug for the treatment of adolescent Stargardt disease (STGD1). This designation is based on interim data from the global Phase III DRAGON clinical trial in adolescent STGD1 patients.
With this designation, Tinlarebant gains all the advantages of Fast Track status, including rolling review, priority review eligibility, and increased engagement with regulatory authorities—factors that will help accelerate the pathway toward U.S. marketing approval.
Belite Chairman and CEO Tom Lin stated that there are currently no approved treatments for STGD1 and that the company will continue advancing the development of Tinlarebant. Clinical data from nearly two years of study is expected to be released by the end of this year.
Lin BioScience emphasized that the designation was granted based on interim data from the ongoing global Phase III DRAGON study in adolescent STGD1 patients, which the FDA believes provides preliminary clinical evidence of substantial improvement in one or more clinically significant endpoints over existing therapies.
Notably, according to the Data Safety Monitoring Board (DSMB), Tinlarebant has continued to demonstrate a favorable safety profile, consistent with previous observations and its mechanism of action. Most participants maintained stable vision over the two-year study period, with average changes of fewer than three letters from baseline, suggesting the drug’s potential to slow disease progression. The DRAGON trial is expected to complete in Q4 2025, including a three-month follow-up period.
Belite’s Chief Scientific Officer Nathan Mata noted that the designation affirms Tinlarebant’s potential to slow or halt disease progression by targeting the underlying pathophysiology of STGD1.
Chief Medical Officer Hendrik Scholl added that STGD1 is a progressive retinal degenerative disease that typically manifests during adolescence and ultimately leads to legal blindness. Although patients often have many decades of life ahead, the profound vision loss drastically impacts their quality of life. The Breakthrough Therapy Designation reflects the potential to bring a new treatment option to patients who currently lack effective therapies.
Tinlarebant has previously been granted multiple regulatory designations for the treatment of STGD1, including Orphan Drug Designation (ODD) by the U.S. FDA, EMA, and Japan’s PMDA; Rare Pediatric Disease (RPD) designation and Fast Track Designation from the U.S. FDA; and Sakigake Designation by Japan’s Ministry of Health, Labour and Welfare (MHLW). Tinlarebant is currently the only ophthalmic candidate on the Sakigake list, and the only one developed by a non-Japanese company. It has the potential to become the world’s first approved treatment for STGD1, tapping into a significant market opportunity.
Stargardt disease has a prevalence of 1 in 10,000 and is the most common form of inherited retinal dystrophy. In the U.S. alone, around 30,000 individuals are affected, yet no effective treatment currently exists. There remains a significant unmet medical need globally. According to a report by a U.S. investment bank, the global STGD1 market is projected to reach USD 1.27 billion by 2030.
Resource: 仁新斯特格病變新藥 再獲美國FDA突破性治療認定
